Ejaz Yousef1, Yelena Korotkaya1, Alyson B Simpson2. 1. From the Divisions of Allergy/Immunology and Pediatric Gastroentrology, Nemours Children Specialty Care, Jacksonville, Florida; and. 2. Simpson Allergy and Asthma, Lansdale, Pennsylvania.
Abstract
Background: Eosinophilic esophagitis (EoE) is a chronic immune and/or antigen-mediated disease characterized by eosinophilic infiltration of mucosa (≥15 eosinophils per high power field) without any secondary etiology. Non-immunoglobulin E mediated mechanisms predominate in EoE. Objective: This review concentrated on a stepwise approach for the allergist working in non-tertiary care private practice. Methods: A medical literature search that focused on several areas of the latest developments in the diagnosis and management of EoE was conducted. Results: There has been a steady increase in the prevalence and incidence of EoE. Clinical symptoms can vary from dysphagia to failure to thrive, depending on the age at presentation; some children develop adaptive behaviors to compensate for dysphagia, such as food preferences and slow eating. The diagnosis is based on a high index of clinical suspicion and is confirmed with endoscopy with biopsies after ruling out other causes of esophageal eosinophilia. Treatment options may include dietary therapy, pharmacologic therapies, or combination therapy. Therapeutic options may also include endoscopic dilation for stricturing disease. Conclusion: Providers should be aware of recent recommendation changes in the diagnostic workup, the role of skin-prick testing, and role of the proton-pump inhibitor as first-line therapy for EoE. Also, clinicians should be aware of the emerging role of empiric dietary therapy as a preferable therapeutic option when compared with the testing-directed diet and the elemental diet. Furthermore, topical glucocorticoid therapies are available, and new developing therapies are being investigated. Reevaluation of esophageal mucosa with biopsies is required approximately 2 months after therapy for a response and after a change in therapies to confirm continued resolution.
Background: Eosinophilic esophagitis (EoE) is a chronic immune and/or antigen-mediated disease characterized by eosinophilic infiltration of mucosa (≥15 eosinophils per high power field) without any secondary etiology. Non-immunoglobulin E mediated mechanisms predominate in EoE. Objective: This review concentrated on a stepwise approach for the allergist working in non-tertiary care private practice. Methods: A medical literature search that focused on several areas of the latest developments in the diagnosis and management of EoE was conducted. Results: There has been a steady increase in the prevalence and incidence of EoE. Clinical symptoms can vary from dysphagia to failure to thrive, depending on the age at presentation; some children develop adaptive behaviors to compensate for dysphagia, such as food preferences and slow eating. The diagnosis is based on a high index of clinical suspicion and is confirmed with endoscopy with biopsies after ruling out other causes of esophageal eosinophilia. Treatment options may include dietary therapy, pharmacologic therapies, or combination therapy. Therapeutic options may also include endoscopic dilation for stricturing disease. Conclusion: Providers should be aware of recent recommendation changes in the diagnostic workup, the role of skin-prick testing, and role of the proton-pump inhibitor as first-line therapy for EoE. Also, clinicians should be aware of the emerging role of empiric dietary therapy as a preferable therapeutic option when compared with the testing-directed diet and the elemental diet. Furthermore, topical glucocorticoid therapies are available, and new developing therapies are being investigated. Reevaluation of esophageal mucosa with biopsies is required approximately 2 months after therapy for a response and after a change in therapies to confirm continued resolution.
Authors: Tetsuo Shoda; Ting Wen; Seema S Aceves; J Pablo Abonia; Dan Atkins; Peter A Bonis; Julie M Caldwell; Kelley E Capocelli; Christina L Carpenter; Margaret H Collins; Evan S Dellon; Michael D Eby; Nirmala Gonsalves; Sandeep K Gupta; Gary W Falk; Ikuo Hirano; Paul Menard-Katcher; Jonathan T Kuhl; Jeffrey P Krischer; John Leung; Vincent A Mukkada; Jonathan M Spergel; Michael P Trimarchi; Guang-Yu Yang; Nives Zimmermann; Glenn T Furuta; Marc E Rothenberg Journal: Lancet Gastroenterol Hepatol Date: 2018-05-03
Authors: Jonathan M Spergel; Marc E Rothenberg; Margaret H Collins; Glenn T Furuta; Jonathan E Markowitz; George Fuchs; Molly A O'Gorman; Juan Pablo Abonia; James Young; Timothy Henkel; H Jeffrey Wilkins; Chris A Liacouras Journal: J Allergy Clin Immunol Date: 2011-12-28 Impact factor: 10.793
Authors: Ikuo Hirano; Evan S Dellon; Jennifer D Hamilton; Margaret H Collins; Kathryn Peterson; Mirna Chehade; Alain M Schoepfer; Ekaterina Safroneeva; Marc E Rothenberg; Gary W Falk; Yehudith Assouline-Dayan; Qiong Zhao; Zhen Chen; Brian N Swanson; Gianluca Pirozzi; Leda Mannent; Neil M H Graham; Bolanle Akinlade; Neil Stahl; George D Yancopoulos; Allen Radin Journal: Gastroenterology Date: 2019-10-05 Impact factor: 22.682
Authors: J Rodríguez-Sánchez; E Gómez Torrijos; B López Viedma; E de la Santa Belda; F Martín Dávila; C García Rodríguez; F Feo Brito; J Olmedo Camacho; P Reales Figueroa; J Molina-Infante Journal: Allergy Date: 2014-05-09 Impact factor: 13.146
Authors: Elizabeth T Schaefer; Joseph F Fitzgerald; Jean P Molleston; Joseph M Croffie; Marian D Pfefferkorn; Mark R Corkins; Joel D Lim; Steven J Steiner; Sandeep K Gupta Journal: Clin Gastroenterol Hepatol Date: 2008-02 Impact factor: 11.382
Authors: Evan S Dellon; Nirmala Gonsalves; Ikuo Hirano; Glenn T Furuta; Chris A Liacouras; David A Katzka Journal: Am J Gastroenterol Date: 2013-04-09 Impact factor: 10.864
Authors: Robert D Pesek; Mallikarjuna Rettiganti; Erin O'Brien; Sarah Beckwith; Caroline Daniel; Chunqiao Luo; Amy M Scurlock; Peggy Chandler; Rebecca A Levy; Tamara T Perry; Joshua L Kennedy; Sheva Chervinskiy; Maryelle Vonlanthen; Helen Casteel; Stephen C Fiedorek; Troy Gibbons; Stacie M Jones Journal: Ann Allergy Asthma Immunol Date: 2017-07-01 Impact factor: 6.347